Updated Hypertension Guidelines: Key Changes and Implications

In August 2025, the American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the evaluation and management of hypertension. These guidelines introduce significant changes in the thresholds for initiating antihypertensive therapy, primarily through the adoption of the Predicting Risk of Cardiovascular Disease EVENTS (PREVENT) equation. This new approach aims to enhance risk assessment for cardiovascular disease (CVD) and improve patient outcomes.

Under Pressure: A Brief Overview of the Updated Hypertension GuidelinesNature

The updated guidelines recommend initiating antihypertensive therapy for patients with stage 1 hypertension (systolic blood pressure [SBP] of 130-139 mm Hg or diastolic blood pressure [DBP] of 80-89 mm Hg) if their CVD risk is 7.5% or higher, a notable decrease from the previous threshold of 10% established in the 2017 guidelines. The PREVENT equation, which evaluates a broader range of risk factors including age, cholesterol levels, and diabetes status, replaces older models that primarily focused on atherosclerotic cardiovascular disease (ASCVD) risk.

Under Pressure: A Brief Overview of the Updated Hypertension GuidelinesNature

The guidelines also revise the parameters for initiating antihypertensive therapy in patients with chronic kidney disease (CKD). Previously, treatment was recommended for patients with stage 3 CKD or greater (eGFR <=59 mL/min/1.73 m²) or stage 1 or 2 CKD with significant albuminuria. The new recommendations advocate for earlier intervention in patients with hypertension and CKD, defined as an eGFR of less than 60 mL/min/1.73 m² or albuminuria of 30 mg/g or higher.

Under Pressure: A Brief Overview of the Updated Hypertension GuidelinesNature

Several other key updates include:

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

• Removal of specific recommendations for calcium channel blockers (CCBs) or thiazide-type diuretics for Black patients, allowing for a more individualized approach to treatment.

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

• For patients with stage 2 hypertension (SBP >=140 mm Hg or DBP >=90 mm Hg), the guidelines suggest initiating treatment with a combination of two first-line antihypertensives to enhance adherence.

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

• The threshold for treating chronic hypertension in pregnancy has been lowered from 160/110 mm Hg to 140/90 mm Hg.

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

• The term "hypertensive urgency" has been replaced with "severe hypertension" without acute target organ damage.

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

The 2025 guidelines are expected to increase the number of patients receiving antihypertensive therapy. Pharmacists and healthcare providers are encouraged to identify patients who may benefit from blood pressure-lowering agents and to utilize the PREVENT equation for comprehensive cardiovascular risk assessment.

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

While the updated guidelines aim to improve patient care, some experts express concerns regarding the potential over-medication of patients with lower risk profiles. Critics argue that the new thresholds may lead to unnecessary treatment and increased healthcare costs.

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

The updated hypertension guidelines represent a significant evolution in the management of this prevalent condition, with the potential to enhance patient outcomes through earlier intervention and a more nuanced understanding of cardiovascular risk.

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines